In-Whan Seong

In-Whan Seong

Auto-generated profile, based on publicly available information

In-Whan Seong

Chungnam National University Hospital

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2010 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SPSeung-Jung Park
Seung-Jung Park
DPDuk-Woo Park
Duk-Woo Park
YKYoung-Hak Kim
Young-Hak Kim
SKSoo-Jin Kang
Soo-Jin Kang
SLSeung-Whan Lee
Seung-Whan Lee
KLKeun Lee
Keun Lee
The potential benefits and risks of the use of dual antiplatelet therapy beyond a 12-month period in patients receiving drug-eluting stents have not been clearly established.

24 April 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
KSKi Bae Seung
Ki Bae Seung
DPDuk-Woo Park
Duk-Woo Park
YKYoung-Hak Kim
Young-Hak Kim
SLSeung-Whan Lee
Seung-Whan Lee
CLCheol Whan Lee
Cheol Whan Lee
SPSeung-Jung Park
Seung-Jung Park
Several studies have compared the treatment effects of coronary stenting and coronary-artery bypass grafting (CABG). However, there are limited data regarding the long-term outcomes of these two interventions for patients with unprotected left main coronary artery disease. We evaluated 1102 patients with unprotected left main coronary artery disease who underwent stent implantation and 1138 patients who underwent CABG in Korea between January 2000 and June 2006. We compared adverse outcomes (death; a composite outcome of death, Q-wave myocardial infarction, or stroke; and target-vessel revascularization) with the use of propensity-score matching in the overall cohort and in separate subgroups according to type of stent. In the overall matched cohort, there was no significant difference between the stenting and CABG groups in the risk of death (hazard ratio for the stenting group, 1.18; 95% confidence interval [CI], 0.77 to 1.80) or the risk of the composite outcome (hazard ratio for the stenting group, 1.10; 95% CI, 0.75 to 1.62). The rates of target-vessel revascularization were significantly higher in the group that received stents than in the group that underwent CABG (hazard ratio, 4.76; 95% CI, 2.80 to 8.11). Comparisons of the group that received bare-metal stents with the group that underwent CABG and of the group that received drug-eluting stents with the group that underwent CABG produced similar results, although there was a trend toward higher rates of death and the composite end point in the group that received drug-eluting stents. In a cohort of patients with unprotected left main coronary artery disease, we found no significant difference in rates of death or of the composite end point of death, Q-wave myocardial infarction, or stroke between patients receiving stents and those undergoing CABG. However, stenting, even with drug-eluting stents, was associated with higher rates of target-vessel revascularization than was CABG.

21 January 2014 in Circulation
Verified
Journal Article
Open access
PDF file
CLCheol Whan Lee
Cheol Whan Lee
JAJung-Min Ahn
Jung-Min Ahn
DPDuk-Woo Park
Duk-Woo Park
SKSoo-Jin Kang
Soo-Jin Kang
SLSeung-Whan Lee
Seung-Whan Lee
SPSeung-Jung Park
Seung-Jung Park
Background—: The risks and benefits of long-term dual antiplatelet therapy remain unclear. Methods and Results—: This prospective, multicenter, open-label, randomized comparison trial was conducted in 24 clinical centers in Korea. In total, 5045 patients who received drug-eluting stents and were free of major adverse cardiovascular events and major bleeding for at least 12 months after stent placement were enrolled between July 2007 and July 2011. Patients were randomized to receive aspirin alone (n=2514) or clopidogrel plus aspirin (n=2531). The primary end point was a composite of death resulting from cardiac causes, myocardial infarction, or stroke 24 months after randomization. At 24 months, the primary end point occurred in 57 aspirin-alone group patients (2.4%) and 61 dual-therapy group patients (2.6%; hazard ratio, 0.94; 95% confidence interval, 0.66–1.35; P =0.75). The 2 groups did not differ significantly in terms of the individual risks of death resulting from any cause, myocardial infarction, stent thrombosis, or stroke. Major bleeding occurred in 24 (1.1%) and 34 (1.4%) of the aspirin-alone group and dual-therapy group patients, respectively (hazard ratio, 0.71; 95% confidence interval, 0.42–1.20; P =0.20). Conclusions—: Among patients who were on 12-month dual antiplatelet therapy without complications, an additional 24 months of dual antiplatelet therapy versus aspirin alone did not reduce the risk of the composite end point of death from cardiac causes, myocardial infarction, or stroke. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01186146.

1 July 2010 in JACC
Verified
Journal Article
Closed access
DPDuk-Woo Park
Duk-Woo Park
KSKi Bae Seung
Ki Bae Seung
YKYoung-Hak Kim
Young-Hak Kim
JLJong-Young Lee
Jong-Young Lee
WKWon-Jang Kim
Won-Jang Kim
SPSeung-Jung Park
Seung-Jung Park

1 March 2008 in JACC
Verified
Journal Article
Closed access
SLSeung-Whan Lee
Seung-Whan Lee
SPSeong-Wook Park
Seong-Wook Park
YKYoung-Hak Kim
Young-Hak Kim
SYSung-Cheol Yun
Sung-Cheol Yun
DPDuk-Woo Park
Duk-Woo Park
SPSeung-Jung Park
Seung-Jung Park

30 June 2009 in Circulation
Verified
Journal Article
Closed access
KCKang-Yin Chen
Kang-Yin Chen
SRSeung-Woon Rha
Seung-Woon Rha
YLYong-Jian Li
Yong-Jian Li
KPKanhaiya L. Poddar
Kanhaiya L. Poddar
ZJZhe Jin
Zhe Jin
SPSeung Jung Park
Seung Jung Park
Background— Whether triple antiplatelet therapy is superior or similar to dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention in the era of drug-eluting stents remains unclear. Methods and Results— A total of 4203 ST-segment elevation myocardial infarction patients who underwent primary percutaneous coronary intervention with drug-eluting stents were analyzed retrospectively in the Korean Acute Myocardial Infarction Registry (KAMIR). They received either dual (aspirin plus clopidogrel; dual group; n=2569) or triple (aspirin plus clopidogrel plus cilostazol; triple group; n=1634) antiplatelet therapy. The triple group received additional cilostazol at least for 1 month. Various major adverse cardiac events at 8 months were compared between these 2 groups. Compared with the dual group, the triple group had a similar incidence of major bleeding events but a significantly lower incidence of in-hospital mortality. Clinical outcomes at 8 months showed that the triple group had significantly lower incidences of cardiac death (adjusted odds ratio, 0.52; 95% confidence interval, 0.32 to 0.84; P =0.007), total death (adjusted odds ratio, 0.60; 95% confidence interval, 0.41 to 0.89; P =0.010), and total major adverse cardiac events (adjusted odds ratio, 0.74; 95% confidence interval, 0.58 to 0.95; P =0.019) than the dual group. Subgroup analysis showed that older (>65 years old), female, and diabetic patients got more benefits from triple antiplatelet therapy than their counterparts who received dual antiplatelet therapy. Conclusions— Triple antiplatelet therapy seems to be superior to dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stents. These results may provide the rationale for the use of triple antiplatelet therapy in these patients.